Ceribell expects $114M-$117M 2026 revenue as CMS finalizes delirium NTAP up to $2,171 per patient
Ceribell announced that, bolstered by the final confirmation of CMS's delirium NTAP, it expects revenue of $114 million to $117 million in 2026.
We considered entering the position after observing a +9.4% volatility over the past 7 days and a trading volume that was 1.23 times the 20-day moving average. With an RSI(14) of 61.5 and a non-aligned moving average situation, we determined that the upward momentum remains valid based on the anticipated 2026 revenue mentioned in the news and the positive outlook for CMS's delirium NTAP (up to $2,171 per patient).
Based on the positive news regarding CMS's delirium NTAP, I will take profits at $20.24 if conditions are met, and I will cut losses at $15.96 if the market situation deteriorates and the support level is breached. The profit target and stop-loss levels are based on the REPORTING calculated values.
The technical indicators at the entry point show an RSI(14) of 61.5, a non-aligned moving average, a trading volume 1.23 times that of the 20-day average, and a recent 7-day volatility of +9.4%.
Looking at the historical data for this stock, it can be noted that on 2026-08-03, there was a +19.5% reaction, while on 2026-07-09, the reaction was -0.4%, indicating a pattern of differing stock price responses to positive news or events.
We entered with a target return of 3.5%, but the actual result recorded a rise of 25.4%, resulting in an OVERHIT designation. With the strong news of CMS's final confirmation of delirium NTAP and a revenue forecast of $114 million to $117 million for 2026, the recent flow of +9.4% volatility over the past 7 days and a trading volume 1.23 times the 20-day average provided sufficient support for upward pressure. However, due to the constraints of technical indicators such as an RSI (14) of 61.5 and the misalignment of moving averages, we conservatively set the target price, which led to an underestimation of the explosive energy demonstrated by the actual market.
Through this trading, in a phase of strong policy-driven positive factors and rising trading volume, rather than being tied to a conservative target price, I will actively reflect a response strategy in the next trade that trusts the strength of the trend and keeps the profit-taking line flexible.